Table 3.

Description of evaluable ABT-526– and ABT-510–treated dogs

Evaluable ABT-526 dogs (n = 58)Evaluable ABT-510 dogs (n = 122)
Histology
    Carcinoma2140
    Lymphoma1716
    Sarcoma1454
    Melanoma45
    Other cancer27
Previous therapy
    Surgery2039
    Chemotherapy3753
    Radiation therapy1218
    Combination surgery, chemotherapy or radiation1920
    None1132
  • NOTE: The evaluable population of dogs are those that are able to receive ABT-526 or ABT-510 for at least 30 days.